Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

14 treatments under study, led by Metagenomics Analysis

Research Leaders

8 sponsors active, led by Institute of Tropical Medicine, Belgium

Related Conditions

Often studied with 11 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 4 (1)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT02089048Phase 1CompletedPrimary

Auranofin PK Following Oral Dose Administration

NCT02105714Completed

Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders

NCT02385058Phase 4Completed

Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population

Showing all 3 trials

Research Network

Common Treatments

  • Metagenomics Analysis1
  • Quinfamide1
  • Stool Culturing For Pathogenic Bacteria1
  • Miniflotac1
  • Cca Rdt1

Active Sponsors

  • Institute of Tropical Medicine, Belgium1
  • National Institute of Allergy and Infectious Diseases (NIAID)1
  • Institut de Recherche en Santé Publique, France1
  • Gadjah Mada University1
  • B.P. Koirala Institute of Health Sciences1

Top Investigators

Related Conditions

  • Strongyloidiasis1
  • Helminthiasis1
  • Cryptosporidium Spp Infections1
  • Giardiasis1
  • Aeromonas Spp Infections1

Activity Timeline